Fortress Biotech AI Stock Analysis
Want to see FBIO full AI Analyst Report?
Fortress Biotech (FBIO) AI Stock Analysis
Fortress Biotech
(NASDAQ:FBIO)
The score is driven primarily by improving financial fundamentals (strong TTM cash generation and reduced leverage) but tempered by concerns about earnings quality and historical volatility. Valuation appears very inexpensive based on the low P/E, while the latest earnings call was broadly constructive on product momentum and 2027 access tailwinds. Technicals are the main drag, with the stock trading below key moving averages and negative MACD.
Fortress Biotech (FBIO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $62.70M
- Dividend Yield
- ―
- Average Volume (3M)
- 286.61K
- Price to Earnings (P/E)
- 0.6
- Beta (1Y)
- 0.87
- Revenue Growth
- 12.34%
- EPS Growth
- ―
- Country
- US
- Employees
- 78
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Fortress Biotech Business Overview & Revenue Model
Company Description
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. The...
Fortress Biotech Earnings Call Summary
The call was strongly positive overall. Management highlighted accelerating Emrosi prescriptions, expanding prescriber adoption, strong refill rates, favorable clinical and safety data, improving payer access, positive EBITDA and a narrowing GAAP loss. The main challenges were the remaining GAAP loss, a lower cash balance, a one-time vendor settlement, temporary prescription volatility following the copay change, ongoing formulary expansion and uncertainty around the timing of 2027 benefits and guidance.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects Emrosi’s key metrics to “continue to trend positively in the coming quarters,” with ASP to “trend higher in the coming quarters”; a national formulary plan covering over 25 million lives is expected to take effect at the beginning of 2027, with impact “beginning in Q1,” and management expects an “upward trend on ASP and improvement in gross to net as the quarters progress in '27.” High-quality coverage was described as 40% of commercial lives, or about 170 million, 180 million lives, with additional formularies expected to come online in 2027; SG&A as a percentage of revenue is expected to be “consistent or a little bit lower,” or to “decrease a little bit or stay consistent.” Management is “probably going to be somewhat apprehensive here in the first half of next year to give any particular guidance,” although “it certainly will be going up in our estimation”; the 5 new representatives hired with a July 1 start are expected to have “a good 2 quarters” to ramp, and prescription volume following the copay change may take “anywhere from 4 to 8 weeks” to recover, with December expected to be “a very good month.”
Fortress Biotech Financial Statement Overview
Summary
TTM results show a notable inflection with strong revenue growth (+223%) and very strong free cash flow (~$125.7M), alongside improved leverage (debt-to-equity ~0.24). However, profitability quality is a key risk: EBIT remains negative and the unusually high net/EBITDA margins suggest meaningful non-recurring or non-operating drivers, and the multi-year history includes recurring losses and negative cash flow, raising durability concerns.
Income Statement
58NeutralBalance Sheet
66PositiveCash Flow
72Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 69.99M | 63.26M | 57.67M | 84.51M | 75.74M | 68.79M |
| Gross Profit | 44.21M | 42.34M | 36.80M | 61.62M | 44.97M | 36.71M |
| EBITDA | 142.71M | -20.16M | -104.49M | -135.72M | -193.69M | -146.17M |
| Net Income | 100.12M | 6.82M | -46.00M | -60.64M | -86.58M | -64.70M |
Balance Sheet | ||||||
| Total Assets | 280.21M | 185.55M | 144.22M | 167.53M | 294.30M | 396.50M |
| Cash, Cash Equivalents and Short-Term Investments | 152.19M | 79.38M | 57.26M | 80.93M | 178.27M | 305.74M |
| Total Debt | 38.95M | 74.30M | 75.96M | 84.66M | 127.34M | 74.98M |
| Total Liabilities | 103.19M | 123.36M | 145.87M | 165.94M | 244.28M | 170.63M |
| Stockholders Equity | 160.00M | 49.87M | 22.74M | 22.54M | 41.72M | 108.67M |
Cash Flow | ||||||
| Free Cash Flow | 125.75M | -65.78M | -95.19M | -136.32M | -182.46M | -132.89M |
| Operating Cash Flow | 125.83M | -65.78M | -80.19M | -128.22M | -179.40M | -116.54M |
| Investing Cash Flow | -86.00K | 10.12M | -15.00M | -2.10M | -22.93M | 40.51M |
| Financing Cash Flow | -59.78M | 77.44M | 70.64M | 32.74M | 75.32M | 148.99M |
Fortress Biotech Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBIO, the sentiment is Negative. The current price of 1.88 is below the 20-day moving average (MA) of 1.93, below the 50-day MA of 2.14, and below the 200-day MA of 2.71, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 42.47 is Neutral, neither overbought nor oversold. The STOCH value of 64.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FBIO.
Fortress Biotech Risk Analysis
Fortress Biotech disclosed 69 risk factors in its most recent earnings report. Fortress Biotech reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksFortress Biotech Peers Comparison
Overall Rating
FBIO64Neutral
CVM42Neutral
EQ42Neutral
UNCY41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 64Neutral | $62.70M | 0.65 | 74.69% | ― | 12.34% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | $22.51M | -0.50 | -202.14% | ― | ― | 73.69% | |
| 42Neutral | $106.20M | -7.32 | -37.33% | ― | -100.00% | 71.65% | |
| 41Neutral | $98.89M | -2.12 | -88.81% | ― | ― | 43.63% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FBIO | Fortress Biotech Inc | 1.88 | -0.73 | -27.97% | |
| CVM | Cel-sci | 1.28 | -5.22 | -80.31% | |
| XBIT | XBiotech Inc. | 1.96 | -0.51 | -20.65% | |
| EQ | Equillium | 1.29 | 0.24 | 22.86% | |
| UNCY | Unicycive Therapeutics, Inc. | 3.55 | -2.22 | -38.47% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 15, 2026
